Trends in cancer imaging

2024-9-1

Environmental pollutants and bad bugs work hand in glove

2024-9-1

Epigenetic control of immunoevasion in cancer stem cells

2024-9-1

Scaling data toward pan-cancer foundation models

2024-9-1

Advisory Board and Contents

2024-9-1

CD4+ T cells in antitumor immunity

2024-9-1

Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes

2024-9-1

Subscription & copyright page

2024-9-1

Bispecific antibodies: advancing precision oncology

2024-8-1

Future perspectives on engineered T cells for cancer

2024-8-1

Small molecules targeting microRNAs: new opportunities and challenges in precision cancer therapy

2024-8-1

Advisory Board and Contents

2024-8-1

Advances in exosomes utilization for clinical applications in cancer

2024-8-1

CFTR and colorectal cancer susceptibility: an urgent need for further studies

2024-8-1

Reconceptualizing mental health in cancer survivorship

2024-8-1

Watch your clock: it matters for immunotherapy

2024-8-1

Mechanisms governing lineage plasticity and metabolic reprogramming in cancer

2024-8-1

Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights

2024-8-1

Subscription & copyright page

2024-8-1

Chromatin as an old and new anticancer target

2024-8-1

The origin of novel traits in cancer

2024-8-1

Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity

2024-8-1

Navigating the biophysical landscape: how physical cues steer the journey of bone metastatic tumor cells

2024-8-1

Biosocial determinants inform on enduring cancer disparities

2024-8-1

Targeting cancer stem cells in multiple myeloma

2024-7-5

PARPi, BRCA, and gaps: controversies and future research

2024-7-1

Metastatic hormone-naïve prostate cancer: a distinct biological entity

2024-7-1

Towards enhancing the predictive value of the microbiota for cancer immunotherapy

2024-7-1

Oncology-respirology: a discipline in dire need

2024-7-1

Advisory Board and Contents

2024-7-1

Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer

2024-7-1

Emerging and extensive clonal evolution in the pancreas

2024-7-1

Current landscape of CD3 bispecific antibodies in hematologic malignancies

2024-7-1

A new BRAF inhibitor breaks resistance barriers

2024-7-1

Transcriptomic subtyping of gastrointestinal malignancies

2024-7-1

Next-generation cancer vaccines and emerging immunotherapy combinations

2024-7-1

Mind the gap: why we need to consider teenage and young adult cancers across the research pipeline

2024-7-1

Subscription & copyright page

2024-7-1

Precision oncology: current and future platforms for treatment selection

2024-7-1

B7-H3: a robust target for immunotherapy in prostate cancer

2024-6-4

Puzzling phenomenon: adult-onset cancer predisposition and pediatric cancer

2024-6-1

Exploiting the metabolic vulnerability of circulating tumour cells

2024-6-1

The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments

2024-6-1

Advisory Board and Contents

2024-6-1

Nanomedicine to aid immunogenic cell death (ICD)-based anticancer therapy

2024-6-1

Subscription & copyright page

2024-6-1

Advancements in combining targeted therapy and immunotherapy for colorectal cancer

2024-5-31

COX2-dependent suppression of anticancer immunity

2024-5-30

Intracranial CAR-T cell delivery in glioblastoma patients

2024-5-22

Lifileucel: the first cellular therapy approved for solid tumours

2024-5-9